奥美医疗(002950) - 2022 Q3 - 季度财报

Revenue and Profitability - The company's revenue for Q3 2022 was ¥932,733,147, representing a 12.29% increase year-over-year, and a total revenue of ¥3,067,161,380.95 for the year-to-date, which is a 31.79% increase compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥93,224,648.75, a decrease of 202.04% year-over-year, while the year-to-date net profit was ¥196,873,537.48, down 40.18% compared to the previous year[3] - Total operating revenue for the current period reached ¥3,067,161,380.95, a significant increase from ¥2,327,252,559.38 in the previous period, representing a growth of approximately 31.7%[16] - Net profit for the current period was ¥196,749,394.55, down from ¥330,867,284.85 in the previous period, reflecting a decrease of approximately 40.5%[17] - The total comprehensive income for the current period was ¥289,534,919.49, slightly down from ¥323,648,414.38 in the previous period, a decrease of about 10.5%[17] Cash Flow and Financial Position - The cash flow from operating activities for the year-to-date was ¥900,860,648.94, showing a significant increase of 275.58% compared to the same period last year[3] - The net cash flow from operating activities improved to ¥900,860,648.94, compared to ¥239,857,506.40 in the previous period, indicating a growth of about 274.5%[19] - The company reported a net cash outflow from investing activities of ¥1,067,174,157.15, compared to a net outflow of ¥941,221,354.73 in the previous period, indicating an increase in cash outflow of about 13.4%[19] - Net cash flow from financing activities was -236,928,160.88 CNY in Q3 2022, compared to -313,448,681.28 CNY in Q3 2021, indicating an improvement year-over-year[20] - The company reported a net decrease in cash and cash equivalents of -382,609,401.33 CNY for Q3 2022, compared to -1,013,433,841.51 CNY in Q3 2021, showing a significant reduction in cash burn[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,542,843,747.46, reflecting a 10.75% increase from the end of the previous year[3] - Total assets as of September 30, 2022, amounted to CNY 5,542,843,747.46, an increase from CNY 5,004,829,011.10 at the beginning of the year[13] - Total liabilities reached CNY 2,634,249,126.42, compared to CNY 2,252,783,574.08 at the beginning of the year[14] - The company's total equity attributable to shareholders at the end of the reporting period was ¥2,907,662,991.66, a 5.62% increase from the end of the previous year[3] - The company's total equity as of September 30, 2022, was CNY 2,908,594,621.04, up from CNY 2,752,045,437.02[14] Shareholder Information - The number of common shareholders at the end of the reporting period was 47,822[10] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[10] Expenses and Financial Performance - The company's basic and diluted earnings per share for Q3 2022 were both -¥0.1472, a decrease of 202.04% year-over-year[3] - The company's research and development expenses decreased by 21.46% year-over-year to ¥45,635,755.64[8] - The financial expenses increased significantly by 1636.59% year-over-year to ¥199,980,941.51, primarily due to exchange losses from the depreciation of the RMB against the USD[8] - The company experienced a loss in investment income of ¥9,128,577.84, contrasting with a gain of ¥23,145,832.72 in the previous period[16] - Basic earnings per share decreased to ¥0.3109 from ¥0.5197, reflecting a decline of approximately 40%[17]